Synaptogenix Inc (SNPX)

[SF Wolf]

kld, I doubt anybody on this board has the scientific expertise to evaluate the biochemistry of Bryostatin and Dr. Alkons research.

Dr. Susanne Wilke, PhD, Chief Executive Officer of Neurotrope, in her presentation at the Noble Financial Capital on 1/30/17 did state:

“we are testing in late stage patients to make the point of a significant reversal (in AD). This treatment should be applicable to moderate to early stage to MCI (mild cognitive impairment) patients.”

So, the company is hypothesizing that success in late stage patients will translate into an early treatment for AD.

If Dr. Wilke is right then John Carroll, editor at END POINTS NEWS, in an article last week discussing the recent AD research failure at Lundbeck and problems at Axovant states what we are all hoping for with Neurotrope:

“If a developer can get through an R&D field littered with huge failures like solanezumab and bapineuzumab and make it to the market with a drug, the payoff would be worth billions in annual revenue.”

https://endpts.com/lundbeck-reads-last-rites-on-another-failed-phiii-alzheimers-program/